Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30,462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.
Hsiehchen D, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H. Hsiehchen D, et al. Among authors: zhu h. Cancer Cell. 2024 Dec 9;42(12):1985-1987. doi: 10.1016/j.ccell.2024.10.017. Epub 2024 Nov 21. Cancer Cell. 2024. PMID: 39577419
Multidisciplinary care for patients with HCC: a systematic review and meta-analysis.
Seif El Dahan K, Reczek A, Daher D, Rich NE, Yang JD, Hsiehchen D, Zhu H, Patel MS, Bayona Molano MDP, Sanford N, Gopal P, Parikh ND, Yopp AC, Singal AG. Seif El Dahan K, et al. Among authors: zhu h. Hepatol Commun. 2023 Apr 26;7(5):e0143. doi: 10.1097/HC9.0000000000000143. eCollection 2023 May 1. Hepatol Commun. 2023. PMID: 37102768 Free PMC article.
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.
Hsiehchen D, Beg MS, Kainthla R, Lohrey J, Kazmi SM, Khosama L, Maxwell MC, Kline H, Katz C, Hassan A, Kubota N, Siglinsky E, Pillai AK, Youssoufian H, Mockbee C, Culm K, Uhlik M, Benjamin L, Brekken RA, Ahn C, Singal AG, Zhu H, Hoshida Y, Yopp AC. Hsiehchen D, et al. Among authors: zhu h. Nat Commun. 2024 Mar 11;15(1):2178. doi: 10.1038/s41467-024-46542-y. Nat Commun. 2024. PMID: 38467639 Free PMC article. Clinical Trial.
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D. Muquith M, et al. Among authors: zhu h. Nat Cancer. 2024 Jul;5(7):1121-1129. doi: 10.1038/s43018-024-00752-x. Epub 2024 Mar 25. Nat Cancer. 2024. PMID: 38528112
PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer.
Zhu M, Wang Y, Lu T, Guo J, Li L, Hsieh MH, Gopal P, Han Y, Fujiwara N, Wallace DP, Yu ASL, Fang X, Ransom C, Verschleisser S, Hsiehchen D, Hoshida Y, Singal AG, Yopp A, Wang T, Zhu H. Zhu M, et al. Among authors: zhu h. Cell Metab. 2024 Aug 6;36(8):1711-1725.e8. doi: 10.1016/j.cmet.2024.05.015. Epub 2024 Jun 19. Cell Metab. 2024. PMID: 38901424
30,462 results
You have reached the last available page of results. Please see the User Guide for more information.